By Turna Ray
CHICAGO Data from a prospectively designed, randomized study involving patients who have undergone a percutaneous coronary intervention suggests that individuals who are carriers of the CYP2C19*2 allele experience lower platelet aggregation, and therefore greater response, to standard-dose Effient than they do to high-dose Plavix.
In the study, called RESET, University of Rome's Gennaro Sardella and colleagues also identified a possible platelet aggregation cutoff above which patients may be more likely to harbor genotypic variations in CYP2C19 that compromise their ability to respond to Plavix.
Although the US Food and Drug Administration has placed a "black box" warning on Plavix to note that patients with certain CYP2C19 genotypes may not respond to the drug, physicians have been reluctant to adopt testing without more specific guidance on how genotypic information can guide dosing. Preliminary data from the RESET trial, presented here this week at the American College of Cardiology's annual meeting by Sardella, may further inform such a genotype-driven dosing strategy.
The data confirms results from other trials suggesting that patients who have undergone PCI and harbor certain CYP2C19 alleles respond better to Daiichi Sankyo/Eli Lilly's Effient (prasugrel) than they do to Plavix (clopidogrel), marketed by Bristol-Myers Squibb and Sanofi-Aventis. Specifically, the findings in RESET corroborate results from a retrospective gene substudy of the GRAVITAS trial, in which Matthew Price and colleagues from the Scripps Clinic found that CYP2C19*2 carriers compared to those with the normal allele experienced increased platelet reactivity despite a double dose of Plavix (150 mg/day).
Meanwhile, a prospective study published by researchers at Brigham and Women's Hospital last November in the Journal of the American Medical Association genotyped more than 300 patients with cardiovascular disease and reported the most detailed genotype-guided dosing data for Plavix to date. In that study, called ELEVATE-TIMI 56, the researchers found that patients with CYP2C19*2 genotypes given triple the maintenance dose of clopidogrel (225 mg/day) experienced the same level of platelet reactivity as patients without the CYP2C19*2 allele who received a 75 mg/day dose of the drug. However, the researchers, led by Jessica Mega, found that in patients who carried two copies of the *2 allele, "doses as high as 300 mg daily did not result in comparable degrees of platelet inhibition."
While the Mega study investigated the influence of genotype on response to increasing doses of Plavix, the Sardella study compared the influence of genotype on response to high-dose Plavix and standard-dose Effient. Also, the Meta study broke down Plavix response by whether patients had one or two copies of the *2 allele, whereas Sardella's study only considered *2 carriers versus non-carriers. The retrospective GRAVITAS genetic substudy, meanwhile, also found that *2 homozygous patients fared worse on Plavix than did heterozygous *2 patients.
It is currently controversial in medical practice to use genetic testing to determine whether patients should be treated with Plavix, since a number of studies have come to divergent conclusions about the association between CYP2C19 genotypes and Plavix response, depending on whether researchers focused on surrogate markers of response, such as platelet reactivity, or patient outcomes in terms of cardiovascular events. Many of these studies have been retrospective in design, involved heterogenous disease populations, or been too small to provide definitive answers. Most doctors are waiting for the FDA to provide more definitive dosing recommendations by genotype before deciding whether to adopt genetic testing in this setting.
RESET
In RESET, the study investigators used a crossover, randomized design to compare the antiplatelet effect of standard-dose Effient (10 mg/day) versus high-dose Plavix (150 mg/day) in patients who were stable after a PCI, but had high on-treatment antiplatelet activity upon receiving moderate- to low-dose Plavix. Researchers looked at the relationship between platelet reactivity and CYP2C19*2 genotype when patients were on Effient and then switched to Plavix, or were first on Plavix and then given Effient.
Original post:
Study: Higher Plavix Dose Doesn't Improve Response for CYP2C19*2 Carriers; Effient May Be Best Option
- Sirt1 improves healthy ageing and protects from metabolic syndrome-associated cancer [Last Updated On: August 17th, 2024] [Originally Added On: May 3rd, 2010]
- A new mouse mutant of the Cdh23 gene with early-onset hearing loss facilitates evaluation of otoprotection drugs [Last Updated On: August 17th, 2024] [Originally Added On: August 2nd, 2010]
- Pharmacogenomics [Last Updated On: August 17th, 2024] [Originally Added On: October 10th, 2011]
- Drug Firms Want More Access to Genetic Specimens - Video [Last Updated On: August 17th, 2024] [Originally Added On: October 14th, 2011]
- India joins genome club -Genomics in India - Video [Last Updated On: August 17th, 2024] [Originally Added On: October 14th, 2011]
- Classic: Weinshilboum: Inherited Variations in Drug and Neurotransmitter Metabolism 1981 - Video [Last Updated On: August 17th, 2024] [Originally Added On: October 14th, 2011]
- Intrinsic Subtypes of Gastric Cancer, Based on Gene Expression Pattern, Predict... - Video [Last Updated On: August 17th, 2024] [Originally Added On: October 24th, 2011]
- Antidepressant Use Increases Significantly - Video [Last Updated On: August 17th, 2024] [Originally Added On: October 28th, 2011]
- Kelan G. Tantisira, MD, MPH - Video [Last Updated On: August 17th, 2024] [Originally Added On: October 31st, 2011]
- Human Security Thesis, personalized medicine, pharmacogenomics, Pharmacogenomics - Introduction - Video [Last Updated On: August 17th, 2024] [Originally Added On: November 8th, 2011]
- Pamela Sklar: 2011 Allen Institute for Brain Science Symposium - Video [Last Updated On: August 17th, 2024] [Originally Added On: November 8th, 2011]
- Pharmacy Doctor Oct 2011 A #1.wmv - Video [Last Updated On: August 17th, 2024] [Originally Added On: November 13th, 2011]
- R. Stephanie Huang, PhD: The Role of Pharmacogenomics and Anticancer Drugs - Video [Last Updated On: August 17th, 2024] [Originally Added On: November 19th, 2011]
- Individualized Molecular Testing for Personalized Medicine - Video [Last Updated On: August 17th, 2024] [Originally Added On: November 21st, 2011]
- Where Science Meets Faith: Anticipating the Future - Video [Last Updated On: August 17th, 2024] [Originally Added On: November 28th, 2011]
- Pharmacogenomics of psychotropic drugs - Video [Last Updated On: August 17th, 2024] [Originally Added On: December 6th, 2011]
- 2008 IPIT Awards Seminar: Hans Hogerzeil - Video [Last Updated On: August 17th, 2024] [Originally Added On: December 7th, 2011]
- Asuragen CLIA Pharmacogenomic Services - Video [Last Updated On: August 17th, 2024] [Originally Added On: December 8th, 2011]
- Pilot Demonstration Projects Group 4: Pharmacogenomics - Alan Shuldiner - Video [Last Updated On: August 17th, 2024] [Originally Added On: December 16th, 2011]
- Pharmacogenomics - Howard McLeod - Video [Last Updated On: August 17th, 2024] [Originally Added On: December 17th, 2011]
- Clinical Implementation of Psychiatric Pharmacogenomics - David Mrazek - Video [Last Updated On: August 17th, 2024] [Originally Added On: January 10th, 2012]
- PROMISE - Bionexus Partnership Launching montage - Video [Last Updated On: August 17th, 2024] [Originally Added On: January 16th, 2012]
- Dr. William Figg: Handling Pharmacogenomic Information - Video [Last Updated On: August 17th, 2024] [Originally Added On: January 19th, 2012]
- Using Payer Data to Analyze Impact of Pharmacogenomic Approaches - Robert Epstein - Video [Last Updated On: August 17th, 2024] [Originally Added On: January 22nd, 2012]
- Dr. Russ Altman on Pharmacogenomics - Video [Last Updated On: August 17th, 2024] [Originally Added On: January 26th, 2012]
- AssureRx Health Secures $8M Financing with Silicon Valley Bank to Support Growth [Last Updated On: August 17th, 2024] [Originally Added On: January 31st, 2012]
- BSc Biomedical Sciences courses at Brunel University - Video [Last Updated On: August 17th, 2024] [Originally Added On: February 1st, 2012]
- Companion Diagnostics Market to Explode as Personalized Medicine Market Catapults to $42 Billion by 2015 [Last Updated On: August 17th, 2024] [Originally Added On: February 3rd, 2012]
- Gaming Wins Big at National Science Foundation's Visualization Challenge [Last Updated On: August 17th, 2024] [Originally Added On: February 14th, 2012]
- SBCE to organise international meet on Molecular Medicine [Last Updated On: August 17th, 2024] [Originally Added On: February 15th, 2012]
- FDA Evaluating MolecularHealth's MASE for Analyzing Post-Market Drug Safety [Last Updated On: August 17th, 2024] [Originally Added On: February 15th, 2012]
- Genome BC Funds $9.8M Project to Identify Subgroups in Medulloblastoma for Personalized Treatment [Last Updated On: August 17th, 2024] [Originally Added On: February 15th, 2012]
- Future US Nucleic Acid Testing Market Outlook [Last Updated On: August 17th, 2024] [Originally Added On: February 16th, 2012]
- China Clears Its First Microarray Platform for in Vitro Diagnostics to Accelerate Personalized Medicine [Last Updated On: August 17th, 2024] [Originally Added On: February 16th, 2012]
- ACLA Says Cuts in Medicare Lab Payments Could Hurt Nascent Personalized Dx Segment [Last Updated On: August 17th, 2024] [Originally Added On: February 20th, 2012]
- OncTerm- Pharmacogenomics - Video [Last Updated On: August 17th, 2024] [Originally Added On: February 21st, 2012]
- A Negative Vote for Vivus Obesity Drug, Says 'FDA Panel Whisperer' [Last Updated On: August 17th, 2024] [Originally Added On: February 22nd, 2012]
- International meet on molecular medicine begins at SBCE [Last Updated On: August 17th, 2024] [Originally Added On: February 24th, 2012]
- Demonstrating Cost Effectiveness of Clinical NGS is Key to Payor Reimbursement, Hospital Uptake [Last Updated On: August 17th, 2024] [Originally Added On: February 24th, 2012]
- Darien High Schoolers fare well at science fair [Last Updated On: August 17th, 2024] [Originally Added On: February 27th, 2012]
- US Hematology & Flow Cytometry Market Future Discussed in New Report Published at MarketPublishers.com [Last Updated On: August 17th, 2024] [Originally Added On: February 29th, 2012]
- ACM Global Central Lab Launches Workshop Series to Share Expert Insights on Navigating Global Clinical Trials with a ... [Last Updated On: August 17th, 2024] [Originally Added On: February 29th, 2012]
- Fitch: Drug Makers Continue to Face Challenges at the Beginning of the Drug Channel [Last Updated On: August 17th, 2024] [Originally Added On: February 29th, 2012]
- Will PCORI's Patient-Centered Comparative Effectiveness Research Track with Personalized Rx? [Last Updated On: August 17th, 2024] [Originally Added On: March 3rd, 2012]
- Generex to Meet with FDA about AE37 HER2 Peptide Vaccine; Companion Dx Path Still Unclear [Last Updated On: August 17th, 2024] [Originally Added On: March 6th, 2012]
- Vermillion's OVA1 Test Assigned Category 1 CPT Code; Stock Jumps [Last Updated On: August 17th, 2024] [Originally Added On: March 7th, 2012]
- Transgenomic Reports Fiscal Year 2011 Financial Results [Last Updated On: August 17th, 2024] [Originally Added On: March 7th, 2012]
- Transgenomic's Q4 Revenues Increase 69 Percent [Last Updated On: August 17th, 2024] [Originally Added On: March 7th, 2012]
- Research and Markets: Molecular Diagnostics: Market Segmentation and Opportunities - Emphasis on NGS and Its Emerging ... [Last Updated On: August 17th, 2024] [Originally Added On: March 7th, 2012]
- AMA Approves Vermillion MAAA Category 1 Code for OVA1; Will it Improve Reimbursement? [Last Updated On: August 17th, 2024] [Originally Added On: March 7th, 2012]
- USPSTF Updating BRCA Testing Recommendations for Asymptomatic Women; Accepting Public Input [Last Updated On: August 17th, 2024] [Originally Added On: March 8th, 2012]
- Global Biochips Market to Reach US$4.6 Billion by 2017, According to New Report by Global Industry Analysts, Inc. [Last Updated On: August 17th, 2024] [Originally Added On: March 10th, 2012]
- WSU venturing into pharmacogenomics - Tue, 13 Mar 2012 PST [Last Updated On: August 17th, 2024] [Originally Added On: March 13th, 2012]
- Research and Markets: Stephens' Detection and Evaluation of Adverse Drug Reactions: Principles and Practice (6th ... [Last Updated On: August 17th, 2024] [Originally Added On: March 14th, 2012]
- With MDx Usage and Costs on the Rise, UnitedHealthCare Urges Reimbursement Reform [Last Updated On: August 17th, 2024] [Originally Added On: March 14th, 2012]
- Bioinformatics Market Outlook to 2015 [Last Updated On: August 17th, 2024] [Originally Added On: March 15th, 2012]
- WSU recruits geneticists in new research venture [Last Updated On: August 17th, 2024] [Originally Added On: March 15th, 2012]
- Pharmacogenomics - Video [Last Updated On: August 17th, 2024] [Originally Added On: March 15th, 2012]
- Free Book Download - Psychiatric Pharmacogenomics - Video [Last Updated On: August 17th, 2024] [Originally Added On: March 16th, 2012]
- PanGenX Takes Semantic-based Approach to Data Integration, Analytics for Personalized Medicine [Last Updated On: August 17th, 2024] [Originally Added On: March 17th, 2012]
- Research and Markets: Bioinformatics Market Outlook to 2015 [Last Updated On: August 17th, 2024] [Originally Added On: March 21st, 2012]
- Quest Launches MDx that May Predict Kidney Transplant Rejection Earlier than Current Methods [Last Updated On: August 17th, 2024] [Originally Added On: March 21st, 2012]
- EMERGE Network Launches Publicly Available Database of Phenotype Identification Algorithms [Last Updated On: August 17th, 2024] [Originally Added On: March 23rd, 2012]
- Prospective Outcomes Trial Shows Agendia's MammaPrint Safely Reduces Chemo Use in Low-Risk Patients [Last Updated On: August 17th, 2024] [Originally Added On: March 26th, 2012]
- Abbott Challenges 'Incorrect Assumptions' in Cost-Effectiveness Study of Xalkori PGx Testing [Last Updated On: August 17th, 2024] [Originally Added On: March 26th, 2012]
- Genoptix Says NGS Melanoma Test Will Not Be Used to Place Patients in Trials for Parent Novartis [Last Updated On: August 17th, 2024] [Originally Added On: March 28th, 2012]
- St. Jude's Evans Receives Pharmacists Assn. Award [Last Updated On: August 17th, 2024] [Originally Added On: March 29th, 2012]
- Perkins Chain Hires New CEO [Last Updated On: August 17th, 2024] [Originally Added On: March 29th, 2012]
- PGx Highlights from American College of Cardiology Annual Meeting [Last Updated On: August 17th, 2024] [Originally Added On: March 29th, 2012]
- Collecting Cancer Data [Last Updated On: August 17th, 2024] [Originally Added On: March 29th, 2012]
- UNC Analysis Finds Beta1-AR Alleles Impact Survival in Patients Treated with Beta-Blockers [Last Updated On: August 17th, 2024] [Originally Added On: March 29th, 2012]
- Q&A: GE Healthcare's Mark Dente on the Challenges of Integrating Genomics Data with EMRs [Last Updated On: August 17th, 2024] [Originally Added On: March 31st, 2012]
- Eastday-Neurosurgeon, geneticist take top prizes in science [Last Updated On: August 17th, 2024] [Originally Added On: March 31st, 2012]
- A New 'Omics Emerges [Last Updated On: August 17th, 2024] [Originally Added On: April 2nd, 2012]
- Up to the Task [Last Updated On: August 17th, 2024] [Originally Added On: April 2nd, 2012]
- NHGRI Plans to Fund More Clinical Sequencing Projects [Last Updated On: August 17th, 2024] [Originally Added On: April 7th, 2012]
- Doctor’s role is key to cancer fight [Last Updated On: August 17th, 2024] [Originally Added On: April 16th, 2012]
- People in the News: Josh LaBaer in as New President of US HUPO and More [Last Updated On: August 17th, 2024] [Originally Added On: April 22nd, 2012]
- Convey, CLC Bio to Provide Combined Software, Hardware NGS Data-Analysis Solution [Last Updated On: August 17th, 2024] [Originally Added On: April 22nd, 2012]
- Downloads & Upgrades: Roche's 454 Software, Omixon Simulation Service, OmicsOffice, and Others [Last Updated On: August 17th, 2024] [Originally Added On: April 22nd, 2012]